布地奈德福莫特罗治疗慢阻肺稳定期与慢阻肺合并肺癌稳定期患者的疗效比较  

Comparison of curative effect of budesonide and formoterol in treatment of stable COPD and COPD complicated with lung cancer

作　　者：吴丹[1] 吕志[2] 黄勇[1] WU Dan LV Zhi HANG Yong(the Second People＇s Hospital of Hefei, Hefei, Anhui 230011, China)

机构地区：[1]合肥市第二人民医院肿瘤放疗科,安徽合肥230011 [2]合肥市第二人民医院呼吸内科,安徽合肥230011

出　　处：《临床肺科杂志》2017年第3期534-537,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨布地奈德福莫特罗治疗慢阻肺稳定期与慢阻肺合并肺癌稳定期患者的疗效比较。方法选取2013年1月-2015年12月就诊于合肥市第二人民医院呼吸内科和肿瘤放疗科的26例慢阻肺稳定期患者和26例慢阻肺合并肺癌稳定期患者,两组除了常规的对症治疗外,均采用布地奈德福莫特罗粉吸入剂治疗,治疗12周后分别测定肺功能、6min步行距离,完成圣乔治呼吸问卷(SGRQ)和CAT问卷及评价呼吸困难程度。结果慢阻肺稳定期患者治疗后,SGRQ中症状评分、活动评分和影响评分均较前有所降低,呼吸困难程度、CAT评分和6min步行距离较前改善,差异有统计学意义(P<0.05),FEV_1、FEV_1%pred、FEV_1/FVC较前有所降低,但差异无统计学意义(P>0.05)。慢阻肺稳定期合并肺癌患者SGRQ中症状评分、活动评分和影响评分均较前增加,症状评分和活动评分虽有增加的趋势,但差异无统计学意义(P>0.05),影响评分较前增加,差异有统计学意义(P<0.05),呼吸困难程度和CAT评分较前增加,6min步行距离较前减少,但差异无统计学意义(P>0.05),FEV_1、FEV_1%pred、FEV_1/FVC较前有所降低,差异有统计学意义(P<0.05)。结论布地奈德福莫特罗粉吸入剂可改善慢阻肺稳定期患者临床症状,提高生活质量,但对于治疗慢阻肺稳定期合并肺癌患者的疗效还有待进一步研究。Objective To compare the curative effect of of budesonide and formoterol in treatment of stable COPD and COPD complicated with lung cancer. Methods The study selected 26 stable COPD patients and 26 COPD patients complicated with lung cancer from January 2013 to December 2015 in the second peopleg hospital of Hefei. The two groups were given related conventional treatment and budesonide and formoterol. 12 weeks later, their lung function and 6 minutes walking distance were determined, and SGRQ, CAT, and mMRC questionnaire were ful- filled. Results After treatment, the SGRQ symptom scores, activities scores and influence scores were significantly lower than before in the stable COPD group. The degree of dyspnea, CAT scores and 6 minutes walking distance were significantly improved than before. The lung function of FEV1 , FEV1% Pred and FEV1/FVC were slightly lower than before. In the COPD complicated with lung cancer group, the SGRQ symptom scores and activities scores were not significantly higher and influence scores were significantly higher than before. The degree of dyspnea, CAT scores and 6 minutes walking distance were not significantly lower than before. The lung function of FEV1, FEV1% Pred and FEV1/FVC were statistically lower than before. Conclusion The clinical symptoms and quality of life in pa- tients with stable COPD could be improved by budesonide and formoterol, but for stable COPD patients complicated with lung cancer, it remains to be further studied.

关 键 词：慢阻肺 慢阻肺合并肺癌 稳定期 布地奈德福莫特罗 肺功能 呼吸问卷 

分 类 号：R563.9[医药卫生—呼吸系统] R734.2[医药卫生—内科学]